Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Navidea Biopharmaceuticals, Inc. < Previous 1 2 Next > Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 July 03, 2024 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB OTC Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024 June 20, 2024 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB OTC Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations January 26, 2024 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB OTC Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release December 01, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB OTC Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock October 05, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel August 10, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities July 31, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination July 28, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer July 27, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down July 13, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets June 30, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock June 16, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment June 16, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update June 07, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice June 02, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down June 01, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market May 22, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer May 11, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications May 08, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit April 27, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694 April 13, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down March 30, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results March 21, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update March 15, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline January 03, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Files Appeal in CRG Case November 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis November 28, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results November 14, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting November 07, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update November 04, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Tickers NAVB < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.